Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals Stock Forecast

Stock Price Forecast

The 23 analysts that cover Regeneron Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $799.87, which forecasts a 5.30% increase in the stock price over the next year. The lowest target is $587 and the highest is $1,057.

Price Target: $799.87 (+5.30%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$587	$799.87	$804	$1,057
Change	-22.72%	+5.30%	+5.84%	+39.15%

Analyst Ratings

The average analyst rating for Regeneron Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Sep '25	Oct '25	Nov '25	Dec '25	Jan '26	Feb '26
Strong Buy	6	6	8	8	9	9
Buy	10	9	8	7	8	7
Hold	6	5	6	7	7	6
Sell	1	1	1	1	1	1
Strong Sell	0	0	0	0	0	0
Total	23	21	23	23	25	23

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Mohit Bansal Wells Fargo	Wells Fargo	Hold Maintains $745 → $800	Hold	Maintains	$745 → $800	+5.32%	Feb 2, 2026
Carter Gould Cantor Fitzgerald	Cantor Fitzgerald	Buy Maintains $740 → $800	Buy	Maintains	$740 → $800	+5.32%	Feb 2, 2026
Gregory Renza Truist Securities	Truist Securities	Strong Buy Maintains $820 → $818	Strong Buy	Maintains	$820 → $818	+7.69%	Feb 2, 2026
Cory Kasimov Evercore ISI Group	Evercore ISI Group	Buy Maintains $750 → $875	Buy	Maintains	$750 → $875	+15.19%	Jan 22, 2026
Gregory Renza Truist Securities	Truist Securities	Strong Buy Maintains $798 → $820	Strong Buy	Maintains	$798 → $820	+7.95%	Jan 8, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

15.50B

Increased by 8.06%

from 14.34B

Revenue Next Year

17.09B

Increased by 10.25%

from 15.50B

EPS This Year

46.22

Increased by 11.42%

from 41.48

EPS Next Year

55.85

Increased by 20.85%

from 46.22

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	16.07B	12.17B	13.12B	14.20B	14.34B	15.50B	17.09B
Revenue Growth	89.14%	-24.26%	7.76%	8.27%	0.99%	8.06%	10.25%
EPS	71.97	38.22	34.77	38.34	41.48	46.22	55.85
EPS Growth	135.81%	-46.90%	-9.03%	10.27%	8.19%	11.42%	20.85%
Forward PE	-	-	-	-	-	16.44	13.60
No. Analysts	-	-	-	-	-	29	23

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027	2028	2029	2030
High	17.5B	19.5B
Avg	15.5B	17.1B
Low	13.9B	15.0B

Revenue Growth

Revenue Growth	2026	2027	2028	2029	2030
High	22.3%	25.5%
Avg	8.1%	10.2%
Low	-3.4%	-3.2%

EPS Forecast

EPS	2026	2027	2028	2029	2030
High	55.62	68.42
Avg	46.22	55.85
Low	36.99	47.20

EPS Growth

EPS Growth	2026	2027	2028	2029	2030
High	34.1%	48.0%
Avg	11.4%	20.8%
Low	-10.8%	2.1%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.